EGFR and non-small cell lung carcinoma: Although ICIs have been found to significantly prolong the survival of advanced NSCLC patients harboring wild-type EGFR, their benefits are limited in NSCLC patients with EGFR mutations (21, 22), with some of these patients even developing hyper-progressive disease (HPD) in response to ICIs treatment (23).